Brief: Qualigen Therapeutics Partners With Td2 For Phase 1 Clinical Development For Treatment Of Advanced Or Metastatic Solid Tumors

Aixcrypto Holdings

17/08/2023 14:19

Aug 17 (Reuters) - Qualigen Therapeutics Inc  QLGN.O :
    * QUALIGEN THERAPEUTICS PARTNERS WITH TD2 FOR PHASE 1
CLINICAL
DEVELOPMENT OF QN-302 FOR THE TREATMENT OF ADVANCED OR
METASTATIC SOLID TUMORS
    * QUALIGEN THERAPEUTICS INC -  PLANS TO INITIATE ACTIVATION
OF
FIRST PHASE 1 CLINICAL TRIAL SITE LATER THIS YEAR
    * QUALIGEN THERAPEUTICS INC -  PLANS TO ENROLL FIRST PATIENT
IN
PHASE 1 DOSE ESCALATION CLINICAL STUDY LATER THIS YEAR
    * QUALIGEN THERAPEUTICS INC - QUALIGEN WILL ENROLL PATIENTS
WITH
ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE FAILED PRIOR
THERAPY

Source text for Eikon:  ID:nGNX31DQ49 
Further company coverage:  QLGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))